Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer-LOGIK 0601 study

Tokujiro Yano, Koji Yamazaki, Riichiroh Maruyama, Shoji Tokunaga, Fumihiro Shoji, Hidefumi Higashi, Sadanori Takeo, Yukito Ichinose, Yoshihiko Maehara

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Introduction: The feasibility of using S-1, a novel oral dihydropyrimidine dehydrogenase (DPD)-inhibitory 5-fluorouracil, as postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer (NSCLC) was analyzed. Methods: Adjuvant chemotherapy consisted of eight courses (2-week administration and 1-week withdrawal) of S-1, at 80-120 mg/body per day in an outpatient setting. From July 2006 through March 2007, 30 patients were enrolled in this multi-institutional trial. Results: The planned eight courses of S-1 administration were accomplished to 17 patients (56.7%; 95% confidence interval 37.4-74.5%). Two patients discontinued the treatment due to the disease recurrence, and therefore the completion rate was calculated to be 60.7%. The completion rate in patients younger than 70 years old was 78.6% while it was 42.9% in those of 70 years old or older. In seven patients including five elderly patients (≥70 years old), S-1 administration was discontinued due to subjective symptoms, such as anorexia, during the early courses. The rate of patients with mild renal impairment (60 ≤ creatinine clearance < 80 ml/min) tended to be higher in the elderly patients than that in the younger patients. Although grade 3 neutropenia (6.7%), anemia (6.7%), thrombocytopenia (3.3%) and digestive hemorrhage (3.3%) were observed, no grade 4 adverse events occurred. Conclusion: Postoperative long-term administration of S-1 seems feasible as adjuvant chemotherapy for NSCLC, with few adverse events except for the early development of anorexia, especially in the elderly patients.

Original languageEnglish
Pages (from-to)184-187
Number of pages4
JournalLung Cancer
Volume67
Issue number2
DOIs
Publication statusPublished - Feb 1 2010

Fingerprint

Oxonic Acid
Feasibility Studies
Adjuvant Chemotherapy
Non-Small Cell Lung Carcinoma
Potassium
Anorexia
Dihydrouracil Dehydrogenase (NADP)
gimeracil
Neutropenia
Fluorouracil
Thrombocytopenia
Anemia

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer-LOGIK 0601 study. / Yano, Tokujiro; Yamazaki, Koji; Maruyama, Riichiroh; Tokunaga, Shoji; Shoji, Fumihiro; Higashi, Hidefumi; Takeo, Sadanori; Ichinose, Yukito; Maehara, Yoshihiko.

In: Lung Cancer, Vol. 67, No. 2, 01.02.2010, p. 184-187.

Research output: Contribution to journalArticle

Yano, T, Yamazaki, K, Maruyama, R, Tokunaga, S, Shoji, F, Higashi, H, Takeo, S, Ichinose, Y & Maehara, Y 2010, 'Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer-LOGIK 0601 study', Lung Cancer, vol. 67, no. 2, pp. 184-187. https://doi.org/10.1016/j.lungcan.2009.03.028
Yano, Tokujiro ; Yamazaki, Koji ; Maruyama, Riichiroh ; Tokunaga, Shoji ; Shoji, Fumihiro ; Higashi, Hidefumi ; Takeo, Sadanori ; Ichinose, Yukito ; Maehara, Yoshihiko. / Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer-LOGIK 0601 study. In: Lung Cancer. 2010 ; Vol. 67, No. 2. pp. 184-187.
@article{e76cb4ca947640098066619a3b2eed8e,
title = "Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer-LOGIK 0601 study",
abstract = "Introduction: The feasibility of using S-1, a novel oral dihydropyrimidine dehydrogenase (DPD)-inhibitory 5-fluorouracil, as postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer (NSCLC) was analyzed. Methods: Adjuvant chemotherapy consisted of eight courses (2-week administration and 1-week withdrawal) of S-1, at 80-120 mg/body per day in an outpatient setting. From July 2006 through March 2007, 30 patients were enrolled in this multi-institutional trial. Results: The planned eight courses of S-1 administration were accomplished to 17 patients (56.7{\%}; 95{\%} confidence interval 37.4-74.5{\%}). Two patients discontinued the treatment due to the disease recurrence, and therefore the completion rate was calculated to be 60.7{\%}. The completion rate in patients younger than 70 years old was 78.6{\%} while it was 42.9{\%} in those of 70 years old or older. In seven patients including five elderly patients (≥70 years old), S-1 administration was discontinued due to subjective symptoms, such as anorexia, during the early courses. The rate of patients with mild renal impairment (60 ≤ creatinine clearance < 80 ml/min) tended to be higher in the elderly patients than that in the younger patients. Although grade 3 neutropenia (6.7{\%}), anemia (6.7{\%}), thrombocytopenia (3.3{\%}) and digestive hemorrhage (3.3{\%}) were observed, no grade 4 adverse events occurred. Conclusion: Postoperative long-term administration of S-1 seems feasible as adjuvant chemotherapy for NSCLC, with few adverse events except for the early development of anorexia, especially in the elderly patients.",
author = "Tokujiro Yano and Koji Yamazaki and Riichiroh Maruyama and Shoji Tokunaga and Fumihiro Shoji and Hidefumi Higashi and Sadanori Takeo and Yukito Ichinose and Yoshihiko Maehara",
year = "2010",
month = "2",
day = "1",
doi = "10.1016/j.lungcan.2009.03.028",
language = "English",
volume = "67",
pages = "184--187",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer-LOGIK 0601 study

AU - Yano, Tokujiro

AU - Yamazaki, Koji

AU - Maruyama, Riichiroh

AU - Tokunaga, Shoji

AU - Shoji, Fumihiro

AU - Higashi, Hidefumi

AU - Takeo, Sadanori

AU - Ichinose, Yukito

AU - Maehara, Yoshihiko

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Introduction: The feasibility of using S-1, a novel oral dihydropyrimidine dehydrogenase (DPD)-inhibitory 5-fluorouracil, as postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer (NSCLC) was analyzed. Methods: Adjuvant chemotherapy consisted of eight courses (2-week administration and 1-week withdrawal) of S-1, at 80-120 mg/body per day in an outpatient setting. From July 2006 through March 2007, 30 patients were enrolled in this multi-institutional trial. Results: The planned eight courses of S-1 administration were accomplished to 17 patients (56.7%; 95% confidence interval 37.4-74.5%). Two patients discontinued the treatment due to the disease recurrence, and therefore the completion rate was calculated to be 60.7%. The completion rate in patients younger than 70 years old was 78.6% while it was 42.9% in those of 70 years old or older. In seven patients including five elderly patients (≥70 years old), S-1 administration was discontinued due to subjective symptoms, such as anorexia, during the early courses. The rate of patients with mild renal impairment (60 ≤ creatinine clearance < 80 ml/min) tended to be higher in the elderly patients than that in the younger patients. Although grade 3 neutropenia (6.7%), anemia (6.7%), thrombocytopenia (3.3%) and digestive hemorrhage (3.3%) were observed, no grade 4 adverse events occurred. Conclusion: Postoperative long-term administration of S-1 seems feasible as adjuvant chemotherapy for NSCLC, with few adverse events except for the early development of anorexia, especially in the elderly patients.

AB - Introduction: The feasibility of using S-1, a novel oral dihydropyrimidine dehydrogenase (DPD)-inhibitory 5-fluorouracil, as postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer (NSCLC) was analyzed. Methods: Adjuvant chemotherapy consisted of eight courses (2-week administration and 1-week withdrawal) of S-1, at 80-120 mg/body per day in an outpatient setting. From July 2006 through March 2007, 30 patients were enrolled in this multi-institutional trial. Results: The planned eight courses of S-1 administration were accomplished to 17 patients (56.7%; 95% confidence interval 37.4-74.5%). Two patients discontinued the treatment due to the disease recurrence, and therefore the completion rate was calculated to be 60.7%. The completion rate in patients younger than 70 years old was 78.6% while it was 42.9% in those of 70 years old or older. In seven patients including five elderly patients (≥70 years old), S-1 administration was discontinued due to subjective symptoms, such as anorexia, during the early courses. The rate of patients with mild renal impairment (60 ≤ creatinine clearance < 80 ml/min) tended to be higher in the elderly patients than that in the younger patients. Although grade 3 neutropenia (6.7%), anemia (6.7%), thrombocytopenia (3.3%) and digestive hemorrhage (3.3%) were observed, no grade 4 adverse events occurred. Conclusion: Postoperative long-term administration of S-1 seems feasible as adjuvant chemotherapy for NSCLC, with few adverse events except for the early development of anorexia, especially in the elderly patients.

UR - http://www.scopus.com/inward/record.url?scp=72449210496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449210496&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2009.03.028

DO - 10.1016/j.lungcan.2009.03.028

M3 - Article

VL - 67

SP - 184

EP - 187

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -